zhangsan Apprendista

Iscritti
 Sesso:  Età: 11 Registrato: 08/07/19 09:00 Messaggi: 88
|
|
Uterine fibroid treatment Market Research Report: Forecast up to 2023 Health Articles | June 21 , 2017
Uterine fibroid treatment Market – Industry for Uterine fibroid treatment is dominated by Europe, This report analyzes uterine fibroid treatment on the basis of its market segments, and current market trends
Uterine fibroids (myoma) are benign (non-cancerous) lumps that grow in the muscular wall of the uterus. They vary in sizes, from minute (a quarter of an inch) to the size of more than16 centimeters. The incidence of uterine fibroid is about 20%–40% in women during their reproductive ages. Occasionally, these fibroids swell up and make the uterus to grow like full visible pregnancy. Mostly, there are more than one fibroid in the uterus. However, fibroids do not always cause any symptoms, their location, and size results to difficulties for few women, including pain, discomfort and heavy bleeding. Uterine fibroid can be of different types such as intramural fibroids, subserosal fibroids, pedunculated fibroids and submucosal fibroids. There can be many reasons for uterine fibroid formation but genetic problems hormonal imbalance and other factors are predominant. The cardinal symptoms of uterine fibroids are heavy menstrual bleeding, abdominal pain, excessive uterine bleeding, increased urinary frequency, anaemia and infertility. Apart from physical morbidity, uterine fibroid ailment is a frequent cause of significant damage of quality of life and a major reason for hysterectomy. Therapy has traditionally based on two extremes: medicinal management, comprising progestins, oral contraceptives and GnRH agonists and surgical management, including myomectomy, hysterectomy, and ablation for most serious cases.
Patients suffering from uterine fibroid problem represent an undeserved and huge market due to the absence of satisfactory medical treatments. Uterine fibroids affects nearly 40% of women in the age group of 30 and 55, including 20 million women in North America and 24 million women in Europe with over 7 million patients worldwide presently undergo various symptom management treatments.
The market for uterine fibroid are divided based on non-hormonal treatment, hormonal treatment, surgical methods and geographically. Non-hormonal treatment are subdivided into non-steroidal anti-inflammatory agents (NSAIDS). Hormonal treatment segmented as Oral contraceptives, ProgestinsAntiprogestins, Gonadotropin-releasing hormone (GnRH) agonists. Surgical Methods are segmented as traditional abdominal myomectomy, laparoscopic or robotic myomectomy, hysteroscopic myomectomy, hysterectomy, uterine artery embolization or fibroid embolization (UAE) and ablation.
View Report-
聽
Some of Major players in uterine fibroid market are Boston Scientific Corporation, Cooper Surgical, C.R. Bard, F. Hoffmann-La Roche Ltd, GE Healthcare, Karl Storz Endoscopy, Richard Wolf Medical Instruments and Siemens Medical Solutions, AbbVie Inc., AstraZeneca, Bayer AG, Eli Lilly and Company, GlaxoSmithKline Pharmaceuticals Limited, Pfizer Inc., Johnson & Johnson and Novartis AG.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
聽
The study is a source of reliable data on:
Market segments and sub-segments
Market trends and dynamics
Supply and demand
Market size
Current trendsopportunitieschallenges
Competitive landscape
Technological breakthroughs
Value chain and stakeholder analysis
The regional analysis covers:
North America (U.S. and Canada)
Latin America (Mexico, Brazil, Peru, Chile, and others)
Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, Luxembourg)
Eastern Europe (Poland, Russia)
Asia Pacific (China, India, Japan, ASEAN, Australia and New Zealand)
Middle East and Africa (GCC, Southern Africa, North Africa)
Request a brochure of this report to know what opportunities will emerge in the rapidly evolving Uterine fibroid treatment Market during 2016- 2023
聽
聽
Technology and Transition Technology Articles | April 23, 2013
Over the last century there has been exponential growth in technology. How able are we to predict the future of technology and what are the social effects of increased technology usage?
Technology and Transition
History and future trends:
The best summary of the history of information technologies is a graph that shows the calculations per second per $1,000 from 1900 to today.[1][2] (Try googling calculations per second per $1,000) What we see when we look at these figures is exponential growth.
Up take of the printing press took hundreds of years; uptake of the radio and TV took decades; uptake of the computer and mobile phones took years. The kitsch and yet astonishing comparison that is usually trotted out in conversations like this is that there is over 100 times more computing power in our smart phone than there was in the Apollo Space Program.
Each time we reach the capacity of one technology, a new one appears that takes the technology to the next level. Vacuum tubes were replaced by transistors, which were replaced by chips, which will probably be replaced by 3 dimensional self-organisin. |
|